491 related articles for article (PubMed ID: 18093216)
1. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.
Gutzmer R; Satzger I; Thoms KM; Völker B; Mitteldorf C; Kapp A; Bertsch HP; Kretschmer L
J Dtsch Dermatol Ges; 2008 Mar; 6(3):198-203. PubMed ID: 18093216
[TBL] [Abstract][Full Text] [Related]
2. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
3. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
[TBL] [Abstract][Full Text] [Related]
4. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
[TBL] [Abstract][Full Text] [Related]
5. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma.
Kretschmer L; Beckmann I; Thoms KM; Mitteldorf C; Bertsch HP; Neumann C
Ann Surg Oncol; 2006 Aug; 13(8):1105-12. PubMed ID: 16865591
[TBL] [Abstract][Full Text] [Related]
6. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
7. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
8. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
[TBL] [Abstract][Full Text] [Related]
9. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma.
Scoggins CR; Bowen AL; Martin RC; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; Hagendoorn L; McMasters KM
Arch Surg; 2010 Jul; 145(7):622-7. PubMed ID: 20644123
[TBL] [Abstract][Full Text] [Related]
10. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
[TBL] [Abstract][Full Text] [Related]
12. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
Gajdos C; Griffith KA; Wong SL; Johnson TM; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2009 Dec; 115(24):5752-60. PubMed ID: 19827151
[TBL] [Abstract][Full Text] [Related]
13. Micrometastasis of a sentinel lymph node in cutaneous melanoma is a significant prognostic factor for disease-free survival, distant-metastasis-free survival, and overall survival.
Moehrle M; Schippert W; Rassner G; Garbe C; Breuninger H
Dermatol Surg; 2004 Oct; 30(10):1319-28. PubMed ID: 15458529
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma.
Kunte C; Geimer T; Baumert J; Konz B; Volkenandt M; Flaig M; Ruzicka T; Berking C; Schmid-Wendtner MH
Melanoma Res; 2010 Aug; 20(4):330-7. PubMed ID: 20526218
[TBL] [Abstract][Full Text] [Related]
17. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma.
Jacobs IA; Chang CK; Salti GI
Am Surg; 2004 Jan; 70(1):59-62. PubMed ID: 14964550
[TBL] [Abstract][Full Text] [Related]
18. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI).
Testori A; De Salvo GL; Montesco MC; Trifirò G; Mocellin S; Landi G; Macripò G; Carcoforo P; Ricotti G; Giudice G; Picciotto F; Donner D; Di Filippo F; Soteldo J; Casara D; Schiavon M; Vecchiato A; Pasquali S; Baldini F; Mazzarol G; Rossi CR;
Ann Surg Oncol; 2009 Jul; 16(7):2018-27. PubMed ID: 19132446
[TBL] [Abstract][Full Text] [Related]
19. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.
Rossi CR; De Salvo GL; Bonandini E; Mocellin S; Foletto M; Pasquali S; Pilati P; Lise M; Nitti D; Rizzo E; Montesco MC
Ann Surg Oncol; 2008 Apr; 15(4):1202-10. PubMed ID: 18165880
[TBL] [Abstract][Full Text] [Related]
20. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
